New Study Links Early-Life PFAS Exposure to Reduced Bone Mineral Density in Adolescents

Overview

A new longitudinal study has established a link between early-life exposure to specific PFAS compounds and reduced bone mineral density (BMD) in adolescents. Researchers tracked a cohort of 218 children from birth to age 12, measuring PFAS concentrations in blood at multiple developmental stages and correlating these with bone density outcomes. The study, published in the Journal of the Endocrine Society, identifies PFNA, PFHxS, and PFOS as the primary compounds of concern for skeletal development. This research adds a significant new health endpoint to the toxicological profile of PFAS contamination and has direct implications for how Australian practitioners conduct site-specific human health risk assessments at legacy contamination sites.

Key details

The study followed 218 participants from a birth cohort, collecting blood samples at key developmental milestones and performing dual-energy X-ray absorptiometry (DEXA) scans at age 12 to measure bone mineral density across the whole body, total hip, and femoral neck regions. The researchers controlled for established confounders including diet, physical activity, body mass index, and socioeconomic factors.

The results demonstrated statistically significant inverse associations between early-life exposure to three specific PFAS compounds and bone mineral density at age 12. Perfluorononanoic acid (PFNA) showed the strongest association with reduced whole-body BMD. Perfluorohexane sulfonate (PFHxS) was linked to reduced hip BMD. Perfluorooctane sulfonate (PFOS) was associated with reduced femoral neck BMD. These associations were observed at exposure levels commonly found in populations living near legacy contamination sites.

The biological mechanism proposed involves PFAS disruption of endocrine pathways that regulate calcium metabolism and osteoblast activity during critical periods of skeletal development. The researchers noted that adolescence is a pivotal period for peak bone mass accrual, and any reduction in BMD during this window may increase the lifetime risk of osteoporosis and fracture.

This is one of the first longitudinal studies to track the skeletal effects of PFAS exposure from birth through to adolescence, providing stronger evidence of causation than cross-sectional designs. The researchers have called for PFAS bone health endpoints to be incorporated into regulatory risk assessment frameworks.

Australian context

The implications of this research for Australian contaminated land practice are significant. The NEPM 2013 Health Investigation Levels (HILs) and the PFAS NEMP 3.0 guidelines are periodically reviewed against the global toxicological evidence base. Historically, developmental endpoints have been the primary driver for reducing default guideline values for contaminants, and PFAS is no exception.

Current PFAS screening criteria in Australia are primarily based on hepatotoxicity, immunotoxicity, and developmental/reproductive effects. The addition of skeletal development as a confirmed health endpoint strengthens the case for further reductions in acceptable exposure thresholds. If bone density effects are incorporated into the next revision of PFAS toxicity reference values, the resulting guideline values for soil, groundwater, and drinking water could decrease further.

For practitioners conducting site-specific risk assessments under the NEPM framework, the study reinforces the importance of selecting appropriate toxicity reference values. Relying solely on the currently published screening values without considering the trajectory of the evolving science leaves site owners exposed to future regulatory updates that could reclassify previously compliant sites as requiring further action.

In practical terms, sites where PFAS concentrations in soil or groundwater are close to the current screening thresholds should be flagged as potentially at risk of exceeding revised criteria when updated toxicity data is incorporated. This is particularly relevant for residential sites and sites near schools, childcare centres, and playing fields where children are the primary sensitive receptors.

Practical implications

This research has several practical consequences for environmental consultants, site owners, and regulators:

• Risk assessment conservatism: Practitioners should consider applying a margin of safety when evaluating PFAS risks at sites with sensitive receptors. Conceptual Site Models should explicitly identify children as the critical receptor and assess exposure pathways accordingly.
• Toxicity reference value selection: Where conducting Tier 2 or Tier 3 risk assessments, consultants should review the latest toxicological literature, including this study, when selecting dose-response parameters. The published NEPM screening values represent a point-in-time snapshot that may not reflect current scientific understanding.
• Long-term liability planning: Site owners and developers acquiring PFAS-impacted land should factor in the likelihood that guideline values will continue to decrease. Remediation strategies that achieve concentrations only marginally below current criteria may prove insufficient under future revisions.
• Health surveillance: For communities living near significant PFAS source sites, this research supports the case for expanded health surveillance programmes that include bone density screening, particularly for children and adolescents.
• Regulatory engagement: Consultants advising on PFAS site management should proactively communicate the evolving evidence base to regulators and clients. Demonstrating awareness of emerging health endpoints strengthens the credibility of risk assessments and management plans.

References and related sources

This article is based on research published in the Journal of the Endocrine Society, as reported by the American Journal of Managed Care (AJMC). Related Australian frameworks include the PFAS NEMP 3.0 (March 2025), NEPM 2013 Schedule B1, and the enHealth guidance on PFAS exposure assessment.

Read the primary source article

Join the discussion on LinkedIn

How iEnvi can help

iEnvi provides specialist PFAS site assessment and management services across Australia. Our contaminated land team delivers detailed site-specific human health risk assessments incorporating the latest toxicological data and exposure pathway modelling. We design and implement remediation strategies for PFAS-impacted sites, from source zone treatment to plume containment and long-term monitoring. For disputed or high-profile PFAS matters, our expert witness specialists provide independent technical opinions and regulatory support.

This is an iEnvi Machete news summary. Prepared by iEnvi to summarise the source article for contaminated land, groundwater, remediation, approvals and site risk professionals.

Need advice on this topic? Speak to an iEnvi expert at hello@ienvi.com.au or 1300 043 684, or contact us online.